This bill requires Maryland counties with volunteer fire companies to provide no-cost preventive cancer screenings to volunteer firefighters, as defined by the bill. Volunteer fire companies must maintain and annually submit a list of their volunteer firefighters to the county, which must then keep this list on file. Counties can meet this requirement by either offering a free annual health exam including cancer screenings or applying for a specific grant to fund advanced screening technologies like multi-cancer blood tests. The law applies to all counties with volunteer fire companies and takes effect July 1, 2026.
SB 866 requires chain restaurants with 20 or more locations in Maryland to display warning icons next to menu items exceeding 1,150mg sodium or 25mg added sugars per serving, starting January 1, 2028. The Maryland Department of Health must create these icons and guidelines by January 1, 2027, and run a public education campaign during 2027 to explain compliance. The bill directly affects large chain restaurants by mandating clear labeling of high-sodium and high-sugar menu items. It defines "high sodium" as 1,150mg per serving and "high added sugars" as 25mg per serving for labeling purposes.
HB 1426 creates a new permit for clinical research pharmacies in Maryland, which are facilities specifically designed to conduct clinical trials. It allows healthcare providers to own these pharmacies under strict conditions, including requiring a licensed pharmacist to be on-site during all operating hours and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations or entities from being classified as "practice of medicine," meaning trial staff no longer need individual medical licenses for their trial-related work. This change aims to streamline clinical research by removing a regulatory barrier that previously required individual licensing for trial staff.
HB 222 requires Maryland public schools and colleges to update policies and education programs to address opioid overdoses. It mandates schools to store naloxone, allow authorized staff and students to possess it, and provide liability protection for good-faith use during overdoses. The bill also adds naloxone's life-saving role to K-12 drug prevention curricula (starting in third grade) and requires annual parent notifications about school naloxone policies. Additionally, schools must report overdose incidents requiring naloxone use to the State Department. This affects all public K-12 schools and state-funded colleges.
HB 494 requires health insurance companies, nonprofit health service plans, and health maintenance organizations (HMOs) operating in Maryland to structure their reimbursements to primary care providers in a way that meets annual investment targets set by the state. Starting February 1, 2026, these entities must report their progress toward meeting these targets when filing new or updated premium rates with the Maryland Insurance Commissioner. The bill amends insurance code sections to mandate this reporting requirement as part of premium rate filings. It takes effect October 1, 2026, focusing on transparency and accountability for primary care funding.
SB 348 requires hospitals and freestanding birthing centers in Maryland to provide specific postpartum support to individuals who have experienced high-risk pregnancies. It mandates that facilities complete referral forms for local health departments, provide resources about postpartum complications (including cardiovascular conditions, chronic disease, substance misuse, and mental health), and call birthing parents 24 to 72 hours after discharge to assess their status. The bill also requires annual reports from health departments detailing referrals made through this process. These provisions apply to all facilities delivering newborns following high-risk pregnancies and take effect October 1, 2026.
HB 598 creates a temporary license for internationally trained physicians to practice medicine in Maryland under specific conditions. It allows the State Board of Physicians to issue a 3-year license (non-renewable) to doctors who hold a WHO-recognized medical degree outside the U.S., completed 2 years of equivalent postgraduate training, practiced medicine for 5 of the last 7 years abroad, passed U.S. medical exams (USMLE Steps 1-3), and meet other criteria like English proficiency and Maryland residency. The license requires physicians to pursue full licensure through board-established pathways after the temporary period ends. This directly affects internationally trained doctors seeking to work in Maryland’s healthcare system, providing a structured but limited pathway to practice.
HB 417 (Public Health - Medetomidine and Xylazine Consumer Protection Act) regulates the sale of veterinary drugs medetomidine and xylazine. It prohibits retailers from selling these products without proof the buyer intends to use them for veterinary, scientific, or institutional purposes, and bans sales to anyone under 21. Retailers must maintain records of sales, including age verification and proof of intended use. Violations carry civil fines up to $6,500 per offense, with penalties deposited into Maryland's Substance Abuse Fund. The bill directly affects pharmacies, veterinary suppliers, and online retailers selling these specific products.
HB 633 requires Maryland health insurers, nonprofit health plans, and health maintenance organizations to cover salpingectomy (surgical removal of fallopian tubes) as a preventive measure for ovarian cancer. It prohibits these insurers from charging copayments, coinsurance, or deductibles for this specific procedure, ensuring no out-of-pocket costs for covered individuals. The exception applies only to high-deductible health plans under federal law, allowing the deductible to apply to the procedure in those cases. This law directly affects women eligible for preventive care and the health insurance providers operating in Maryland.
SB 489 modifies Maryland's licensing rules for physicians trained at international medical schools. It exempts applicants who provide evidence of completing two years of postgraduate training accredited by ACGME-I or another board-recognized body from standard educational requirements. These physicians would be permitted to practice medicine only during their initial license term under mandatory supervision, as specified by the Board. The bill takes effect October 1, 2026, directly affecting international medical graduates meeting these specific training criteria.